Tumors bearing homologous recombination deficiency are extremely sensitive to DNA double strand breaks induced by several chemotherapeutic agents. ATM gene, encoding a protein involved in DNA damage response, is frequently mutated in colorectal cancer (CRC), but its potential role as predictive and prognostic biomarker has not been fully investigated. We carried out a multicenter effort aimed at defining the prognostic impact of ATM mutational status in metastatic CRC (mCRC) patients. Mutational profiles were obtained by means of next-generation sequencing. Overall, 35 out of 227 samples (15%) carried an ATM mutation. At a median follow-up of 56.6 months, patients with ATM mutated tumors showed a significantly longer median overall survival (OS) versus ATM wild-type ones (64.9 vs 34.8 months; HR, 0.50; 95% CI, 0.29-0.85; P = 0.01). In the multivariable model, ATM mutations confirmed the association with longer OS (HR, 0.57; 95% CI, 0.33-0.98; P = 0.04). The prognostic impact of ATM mutations was independent from TP53 mutational status and primary tumor location. High heterogeneity score for ATM mutations, possibly reflecting the loss of wild-type allele, was associated with excellent prognosis. In conclusion, we showed that ATM mutations are independently associated with longer OS in patients with mCRC.
repair via both BRCA1-driven homologous recombination and non-homologous end-joining pathways, as well as in the G1/S cellular checkpoint activation through its major targets p53 and CHK2 7 .
Germline and somatic mutations involving homologous recombination related genes, including ATM, are predicted to confer an enhanced platinum sensitivity 8 . Specifically, ATM deficient tumors display a higher sensitivity to DNA DSB-inducing treatments 9 and loss of function mutations affecting the ATM gene could confer a vulnerability to DNA-damaging agents, especially in combination with p53 deficiency [10] [11] [12] [13] . Because of the consistent prevalence of ATM mutations in CRC (7% in non-hypermutated cases) 14 and their potential crucial role as biomarker of chemosensitivity to platinum salts and topoisomerase inhibitors, ATM mutations would therefore characterize mCRC patients with a more favourable outcome, at least when eligible for combination chemotherapy. Moving from this background, we performed a translational study aimed at assessing the prognostic relevance of ATM mutational status in mCRC patients.
Materials and Methods
Patients population. We retrieved pre-treatment tumor tissue blocks of initially unresectable mCRC patients treated at two Italian Institutions (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and Azienda Ospedaliero-Universitaria Pisana). Clinical, pathological and molecular characteristics at the time of diagnosis of metastatic disease were collected, including age, gender, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), primary tumor location (right-vs left-sided), primary tumor resection (yes vs no), time-to-metastases (synchronous vs metachronous), number of metastatic sites (1 vs >1), RAS and BRAF mutational status, and MSI status. All included patients received at least one treatment line with doublet or triplet regimens with or without monoclonal antibodies according to standard clinical practice. The study was approved by the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Institutional Review Board (study ID: INT 117/15) and conducted according to the ethical principles for medical research involving human subjects adopted in the Declaration of Helsinki. All patients signed a written informed consent.
Next-generation sequencing analysis. We centrally collected formalin-fixed paraffin-embedded archival tumor tissue blocks. Next-generation sequencing (NGS) data were obtained through the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies) with the Ion-Torrent ™ Personal Genome Machine platform (Life Technologies), as previously described 15, 16 and detailed in Supplementary Methods (see Supplementary Information). ATM and TP53 mutational status was obtained, and RAS and BRAF mutational status was centrally confirmed. Heterogeneity score (HS) of ATM mutations was calculated as previously described by Normanno et al. 17 . Briefly, the mutant allelic frequency was normalized for the neoplastic cell content, and the HS was calculated by multiplying by 2 the frequency of mutant alleles in neoplastic cells as somatic mutations usually involve only one allele.
Statistical analysis.
Chi-square test or fisher exact test were used, as appropriate, to evaluate the association between ATM mutational status and the other relevant clinical and pathological patients' characteristics. Overall survival (OS) was calculated as the time from diagnosis of metastatic disease to the death from any cause. Since chemotherapy sensitivity putatively caused by ATM mutations may be boosted by the concomitant presence of www.nature.com/scientificreports www.nature.com/scientificreports/ TP53 mutations 10 or primary tumor sidedness due to enrichment of mesenchymal and stem-like subtypes in right-sided tumors 18 we also evaluated the prognostic impact of combined ATM and TP53 mutational status assessment as well as the prognostic impact of combined ATM mutational status and primary tumor location. The Kaplan-Meier method and the Cox proportional-hazards model were used for survival analyses. Hazard ratios (HRs) together with 95% confidence intervals (CI) were provided. Statistical significance threshold was set to a two-tailed 0.05 value. R software (version 3.5.0) and RStudio software (version 1.1.453) were used for Statistical analyses.
Results
Clinical, pathological and molecular features of ATM mutated mCRC. As detailed in the Consort diagram ( Supplementary Fig. S1 in Supplementary Information), the final study population included a total of 227 patients, of whom 35 (15%) had ATM mutated tumors and 192 (85%) ATM wild-type tumors. TP53 mutations were found in a total of 148 (65%) of samples, of whom 24 (69%) in the ATM mutated subgroup and 124 (65%) in ATM wild-type one (P = 0.65). Table 1 shows patients' demographics and disease characteristics, overall and according to ATM mutational status. Of note, ATM mutations were not significantly associated with specific clinical and molecular features. The exposure to specific agents approved for mCRC and the number of treatment lines received are summarized in Supplementary Table S1 (see Supplementary Information). 1  MSI  K610T  60  R248Q  70  G12V  70  ----E1464VfsTer8  44   2  NA  E1325Stop  94  R175C  180  --------3  MSS  D2870H  52  --G12S  114  ----R1450Stop  106   4  MSS  R3047Stop  88  --G12D  58  ----R1450Stop  46   5  MSI  R337C  32  --G13D  36  ----I1307K  156   6  MSS  P3050L  254  P278S  173  Q61H 120 F1928fs*9  206  R27H + R17H  340  ----V600E  468  --30  MSS  F858L  300  V274F  66  --------31  MSS  R337H  20  --A146T  140  ------32  MSS  R2912G  116  R2912G  400  --G12S  120  ----33  MSS  G2695V  46  G245S  60  ------R1450Stop  50   34  MSS  V410A  132  R273C  108  G12V  -----R1450Stop  62   35  MSS  F858L  146  R282W  202  ------Q1291Stop  84   Table 2 . Specific mutations found in ATM gene with concomitant "trunk" mutations (affecting TP53, KRAS, NRAS, BRAF and APC) with relative heterogeneity score. Abbreviations. HS: heterogeneity score. MSI: microsatellite instability. MSS: microsatellite stability.
www.nature.com/scientificreports www.nature.com/scientificreports/ specific mutations found in ATM gene and concomitant "trunk" mutations affecting TP53, KRAS, NRAS, BRAF and APC, with relative HS. The median HS for ATM mutations was 116 (IQR, 51-197).
Prognostic role of ATM mutations in mCRC patients. At a median follow-up of 56.6 months (95% CI, 46.3-62.1), patients with ATM mutated tumors showed a significantly longer median OS than patients with ATM wild-type tumors (64.9 versus 34.8 months; HR, 0.50; 95% CI, 0.29-0.85; P = 0.01) (Fig. 1) . In the multivariable model (Table 3) , including other covariates significantly associated with OS, the presence of ATM mutations confirmed its association with improved OS (HR, 0.57; 95% CI, 0.33-0.98; P = 0.04), along with left-sided primary tumor location (P = 0.005), primary tumor resection (P = 0.003), metachronous metastases (P = 0.005) and the presence of a single site of metastasis (P = 0.03).
Among patients with ATM mutated tumors, an HS ≥ 100 for ATM mutations was associated with a longer median OS compared with an HS < 100 (70.1 versus 38.5 months; HR, 0.28; 95% CI 0.09-0.85; P = 0.02) (Fig. 2) . Therefore, when using patients with wild-type ATM as reference, the HR for patients with ATM mutated tumors and HS < 100 was 0.91 (95% CI, 0.44-1.86; P = 0.79), whereas it relevantly decreased for patients with ATM mutated tumors and HS ≥ 100 (HR, 0.57; 95% CI, 0.39-0.84; P = 0.004).
Of note, no prognostic significance was observed for TP53 mutational status (P = 0.79), and the prognostic impact of ATM mutations was completely independent from the concomitant presence of TP53 mutations ( Supplementary Fig. S2 in Supplementary Information) or primary tumor sidedness ( Supplementary Fig. S3 in Supplementary Information) .
Finally, since we performed a massively parallel sequencing of multiple cancer-related genes, we assessed the prognostic value of the top mutated genes (i.e. those found mutated in at least 5% of samples: ATM, KRAS, BRAF, NRAS, APC, PIK3CA, SMAD4, FBXW7 and MET) and applied the Benjamini-Hochberg procedure in order to decrease the false discovery rate, demonstrating that the P-value for ATM mutational status remained significant (P = 0.04) ( Supplementary Table S2 in Supplementary Information).
Discussion
Given the crucial role of ATM activity in orchestrating the DDR, relevant phenotypic spillover is awaited upon its loss. However, as a result of both biological complexity of the DDR network and heterogeneity across different studies, no conclusive clinical data are available on ATM prognostic and/or predictive impact.
In early stage CRC, low ATM expression has been previously associated with worse outcomes. In a series of 330 early CRCs, the presence of ATM expression detected by immunohistochemistry (IHC) was associated with disease-free survival and OS benefit when considering patients who underwent adjuvant treatments (N = 33) 19 . Similar results have been confirmed by a subgroup analysis of the VICTOR trial, which included stage II/III CRC patients undergoing adjuvant fluoropyrimidine-based chemotherapy 20 . Regarding the metastatic setting, a recent monocentric study showed that ATM deficiency (as primarily assessed by IHC) may be associated with improved OS following oxaliplatin-based first-line treatment, but not irinotecan-based one 21 . Discrepancy in available evidences might be related to the different prognostic role of ATM loss of function according to disease stage, similarly to what reported for MSI 22 , and the confounding effects derived from the heterogeneity of available regimens and treatment sequences used for metastatic disease. www.nature.com/scientificreports www.nature.com/scientificreports/ This is the larger available study assessing the role of ATM mutations as prognostic biomarker in mCRC. Here, the presence of ATM mutations was independently associated with improved OS (adjusted HR, 0.57; 95% CI, 0.33-0.98; P = 0.04). These results suggest that ATM mutations might identify a biologically distinct disease with a survival advantage in the metastatic setting linked, at least in part, to an increased chemosensitivity. Intriguingly, patients with ATM mutations and an HS ≥ 100, showed the best outcomes in terms of OS. As previously described by Normanno et al. 17 , HS virtually corresponds to the fraction of neoplastic cells bearing a specific mutation. Specifically, an HS > 100 might reflect the loss of the wild-type allele. HS might help identifying tumors with a "functional knock-out" of ATM that lose their ability of properly coping with DNA damage. Therefore ATM HS should be taken into account by future studies and potentially correlated with functional data.
From a preclinical point of view, p53 is one of the most characterized ATM targets, required for G1/S cell arrest and apoptosis. Conceptually, drugs inducing high amount of DNA damage in S phase in cells with both DNA repair and G1/S-G2/M checkpoint deficiency (such as those bearing both ATM and TP53 mutations) are likely to induce a mitotic catastrophe-mediated cell death 23 . However, we did not find any clinically relevant interaction between ATM and TP53 mutational status in impacting on OS ( Supplementary Fig. S2 in Supplementary Information). It must be pointed out that, even if ATM or CHK2 suppression preferentially sensitizes p53 deficient tumors to genotoxic drugs, a chemosensitivity status driven by ATM deficiency might occur independently from TP53 24 .
In addition, an enrichment of ATM mutations is expected in mCRC patients with right-sided tumors 18 , MSI-high 14 or CMS1 ones 25 . In our study, the prognostic impact of ATM mutational status was independent from www.nature.com/scientificreports www.nature.com/scientificreports/ primary tumor location status ( Table 3 and Supplementary Fig. S3 in Supplementary Information) , even if the low number of patients with ATM mutations and right-sided mCRC highlights the need of larger datasets to specifically assess the impact of DDR alterations according to primary tumor location or disease subtypes.
Our study has some limitations. For instance, despite the strong rationale making ATM mutational status a candidate biomarker of response to oxaliplatin and/or irinotecan [26] [27] [28] [29] , we have not considered response rate or progression-free survival because of the heterogeneity of treatment regimens as per standard practice (fluoropyrimidine monotherapy, doublet or triplet chemotherapy regimens associated or not with anti-VEGF or anti-EGFR). Of course, an integrated assessment of both protein expression and mutational status would be necessary for identifying all tumors with clinically relevant ATM loss of function. In fact, other mechanisms might account for ATM reduced activity, such as low expression due to promoter methylation 30 . Indeed, a comprehensive assessment of the DDR network on a proteomic scale is expected to reach the best accuracy for predicting chemosensitivity.
Beyond being a sole biomarker of chemosensitivity, ATM mutations might predict response to DDR-targeting agents paralleling recent achievements in other clinical settings, such as castration-resistant prostate cancer (CRPC). Indeed, in the TOPARP-A phase II trial CRPC patients bearing alterations in homologous recombination repair genes displayed a high response rate to the PARP inhibitor olaparib (including 4 out of 5 patients with tumors bearing ATM mutations) 31 . Similar therapeutic approach would be backed by a strong preclinical rationale also in CRC 32 . The reader is referred to Choi et al. 33 for reviewing potential synthetic lethality strategies (e.g PARP1 or ATR inhibitors) in ATM deficient tumors.
In conclusion, our study suggests that ATM mutations with high HS might characterize a subset of mCRC at better prognosis. From this background, further investigations are needed to cover crucial unresolved issues such as the assessment of functional relevance of specific ATM mutations and their predictive role upon specific DNA damaging and/or DDR-targeting agents. Indeed, synthetic lethality strategies might be preferentially used in ATM deficient tumors, while ATM proficient tumors might be sensitized to conventional therapies by ATM inhibitors 34 . Thus, ATM mutational status could enter the clinical decision-taking process in parallel with the development of specific targeted strategies.
